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Extensively drug-resistant (XDR) tuberculosis (TB), which is resistant to both first- and second-line antibiotics, is an
escalating problem, particularly in the Russian Federation. Molecular fingerprinting of 2348 Mycobacterium tuberculosis
isolates collected in SamaraOblast, Russia, revealed that 72% belonged to the Beijing lineage, a genotype associated with
enhanced acquisition of drug resistance and increased virulence. Whole-genome sequencing of 34 Samaran isolates, plus
25 isolates representing global M. tuberculosis complex diversity, revealed that Beijing isolates originating in Eastern
Europe formed a monophyletic group. Homoplasic polymorphisms within this clade were almost invariably associated
with antibiotic resistance, indicating that the evolution of this population is primarily driven by drug therapy. Re-
sistance genotypes showed a strong correlation with drug susceptibility phenotypes. A novel homoplasic mutation in
rpoC, found only in isolates carrying a common rpoB rifampicin-resistance mutation, may play a role in fitness com-
pensation. Most multidrug-resistant (MDR) isolates also had mutations in the promoter of a virulence gene, eis, which
increase its expression and confer kanamycin resistance. Kanamycin therapy may thus select for mutants with increased
virulence, helping preserve bacterial fitness and promoting transmission of drug-resistant TB strains. The East European
clade was dominated by two MDR clusters, each disseminated across Samara. Polymorphisms conferring fluoroquinolone
resistance were independently acquired multiple times within each cluster, indicating that XDR TB is currently not widely
transmitted.
[Supplemental material is available for this article.]
Multidrug-resistant (MDR) tuberculosis (TB), which is resistant to
at least isoniazid and rifampicin, is a growing threat to national
tuberculosis programs worldwide. MDR TB patients are more dif-
ficult and costly to treat and remain infectious for longer, and rates
of default, failure and death are higher. Extensive resistance (XDR),
defined asMDR plus resistance to any fluoroquinolone and at least
one of the second-line injectable agents (kanamycin, capreomycin,
or amikacin), further decreases chances of treatment success and
survival (Drobniewski et al. 2005; Gandhi et al. 2006; Migliori et al.
2008; Shah et al. 2008; Kliiman and Altraja 2009;Wright et al. 2009;
Leimane et al. 2010). So far, co-infection of HIV and XDR TB has
proved largely fatal (Gandhi et al. 2006).
The problem of drug-resistant TB is particularly acute in
countries of the former Soviet Union, where almost half of all cases
are resistant to at least one drug; the MDR TB rate exceeds 10%
among new cases; and XDR TB can account for up to a quarter of
MDR TB cases (Drobniewski et al. 2005; Kliiman and Altraja 2009;
Wright et al. 2009; Leimane et al. 2010).
In Samara Oblast (a region of the Russian Federation with
a population of 3.3 million), TB incidence and prevalence rates
reached 86.8 and 162.5 per 100,000 population in 2009. Extremely
high rates of MDR TB (20% among new and 43% among pre-
viously treated cases) are coupled with a fast growing epidemic
of HIV with the number of HIV-positive cases reaching 40,000
in 2010 (Drobniewski et al. 2005; Samara Oblast Tuberculosis
Dispensary 2009; Samara AIDS Center Epidemiological Update
2010 [http://www.noaids.ru/r/11/]). Prolonged hospitalization
(minimum, 3 mo) is compulsory for smear/culture-positive pa-
tients, and HIV-infected patients stay at the same hospitals with
other patients, including drug-resistant cases. Institutional in-
fection control measures are not fully implemented, providing
opportunities for MDR/XDR TB super-infection of patients.
On the basis of single nucleotide polymorphism (SNP) anal-
ysis, Baker et al. (2004) determined that the global Mycobacterium
tuberculosis complex (MTBC) population could be divided into five
core lineages, here designated Beijing, CAS, EuroAmerican, EAI,
and Mycobacterium bovis (more typically an animal pathogen). By
use of large sequence polymorphisms (LSPs), Gagneux et al.
(2006a) confirmed these groupings and defined twoMycobacterium
africanum lineages: West African-1 and -2. In a previous study, we
found that approximately two-thirds of TB cases in Samara were
caused by strains belonging to the Beijing lineage (Drobniewski
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et al. 2005). There was evidence that Beijing isolates were associ-
ated with drug resistance and caused radiologicallymore advanced
disease. Several other studies have also linked the Beijing geno-
type with greater virulence (for review, see Nicol and Wilkinson
2008).
In this study, we used a whole-genome sequencing approach
to examine the microevolution of Beijing strains, collected in
Samara, focusing on the acquisition and spread of drug resistance.
Results
Molecular fingerprinting of M. tuberculosis strains circulating
in Samara
We analyzed theM. tuberculosis strain family distribution of 2348
isolates (one per patient) collected in 2008–2010 from across
Samara Oblast. In this population, by spacer-oligonucleotide
(spoligotype) analysis, 71.8% of strains shared the Beijing geno-
type. The remainder belonged mostly to the EuroAmerican lin-
eage (22.4%), including the T, Haarlem, and LAM families. CAS
and EAI lineages accounted for 0.5% of the analyzed population
(Fig. 1A).
All Beijing isolates (n = 1,685) were typed using a panel of
eight variable number tandem repeat (VNTR) loci, which are highly
discriminatory for this lineage (Nikolayevskyy et al. 2006). Clus-
tering based on identity at all eight loci revealed that two VNTR
types, containing 341 (20.2%) and 160 (9.5%) isolates, were domi-
nant in the population (Fig. 1B). A further 692 (41.1%) isolates
clustered into groups of size 72 to two, while 492 (29.2%) had fin-
gerprints that were unique in the collection.
Selection of MTBC isolates for genome sequencing
Two EuroAmerican and 32 Beijing isolates from Samara were
chosen for sequencing. Selection of Beijing isolates, based on
VNTR data, covered the breadth of diversity, as well as deep se-
quencing of common VNTR clones in approximate proportion to
their epidemiological abundance (Fig. 1B). One Beijing strain
originally isolated from Estonia was also selected. Over 10 years,
this strain grew from causing a few cases, to dominate the country’s
M. tuberculosis population (Kruuner et al. 2001). Brown et al. (2010)
have demonstrated that global MTBC diversity is reflected in
strains circulating in London. Based on VNTR typing, 23 London
isolates were selected to represent maximum variability across the
entire MTBC and particularly within the Beijing lineage. Finally,
the reference strain, H37Rv, was resequenced.
SNPs and phylogenetic analysis
Sequence reads for each of the 58 MTBC isolates were mapped
against the reference genome, M. tuberculosis H37Rv. A total of
11,854 polymorphic sites were identified, an average of one every
386 bp (Supplemental Data 1). A phylogeny constructed from
these SNPs was congruent with the spoligotype families and sup-
ports that previously established through analyses of SNPs and
LSPs (Fig. 2; Baker et al. 2004; Gagneux et al. 2006a). The four M.
tuberculosis lineages are well defined, and isolates from different
lineages are separated by about 2000 SNPs. Isolates from within
a lineage are separated up to 800 SNPs, with the EuroAmerican
strains appearing the most diverse. Eighty-three SNPs shared by all
members of the four M. tuberculosis lineages discriminated them
from the M. africanum and M. bovis isolates.
In relation to the diverse London Beijing isolates, with one
exception, the Beijing isolates from Samara formed a single clade.
The Estonian isolate and one London isolate, from a patient of
Eastern European ethnicity, fell into the Samara clade. Comparison
of the SNPs we identified, with those determined to definemodern
versus ancient Beijing subtypes (Schu¨rch et al. 2011), revealed that
the exceptional Samara isolate belonged to the ancient subtype,
whereas all other Beijing isolates, including those from London,
were of the modern subtype.
Structural variation
Three large deletions shared by East European Beijing isolates
corresponded to RD105, RD207, and RD181, which define the
modern Beijing sublineage (Gagneux et al. 2006a). No large de-
letions specific to either East European Beijing type, clade A or
clade B, were discovered. Unmapped reads were assembled de
novo, and resulting contigs were compared with completed M.
tuberculosis genome sequences. All contig sequences were found in
strains belonging to the EuroAmerican lineage, indicating that the
evolutionary events detected correspond to deletions within that
lineage or specifically H37Rv. The observed lack of horizontal DNA
acquisition is consistent with previous reports (Hirsh et al. 2004).
Figure 1. Molecular fingerprinting of SamaranM. tuberculosis isolates. (A) Prevalence of spoligotype families (n = 2350) (Vitol et al. 2006). (B) Prevalence
of Beijing family VNTR types with cluster size of 10 or more (n = 1685). (Inset) VNTR types of isolates selected for sequencing (n = 32).
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Correlation of VNTR types with SNP clustering
Within the Beijing lineage, VNTR clustering showed a high degree
of consistency with the SNP-derived phylogeny, exhibiting ho-
moplasy at a single locus between VNTR types 24 and 29 (Fig. 3).
Isolates with VNTR pattern 12 were the most diverse, exhibiting
polymorphism at over 200 nucleotide positions. It is notable that
for this VNTR pattern, the number of repeats at each locus is the
most common number of repeats at that locus across the collec-
tion, suggesting that it represents the ancestral pattern of the East
European isolates.
Within the East European group, the phylogeny revealed two
clearly distinct clades of highly related isolates. The clades, des-
ignated A and B, each included isolates of several VNTR types.
Within each of these clades, there were as few as 20 SNPs sepa-
rating isolates with different VNTR patterns. Thus, isolates of
different VNTR types can be more closely related than those that
share a pattern.
Clade A included all sequenced members of the first- and
fourth-most prevalent VNTR clusters in the population, types
4 and 17, which differ at a single VNTR locus, as well as two small
clusters (less than 10 isolates). Assuming that all isolates be-
longing to at least these four VNTR clusters are members of clade
A, we estimate that ;25% of the Beijing
family in Samara belongs to this clade.
Clade B isolates shared six of eight VNTR
loci and included all the sequenced
isolates of VNTR cluster 24, the second-
most common type in the population, plus
two other clusters. Clade B is thus esti-
mated to represent >11% of circulating
Beijing strains. Neither clade showed any
association with the geographic origin
of the patient within Samara (Supple-
mental Fig.).
The profound differences in the
number of SNPs between and within dif-
ferent VNTR clusters indicates that, in
this high incidence region, VNTR typing
alone does not accurately reflect true
clonal prevalence, significantly under-
estimating the dominance of the com-
monest strains.
Adaptive selection
M. tuberculosis is an obligate human
pathogen, and evolutionary pressure is
likely dominantly mediated by the host
immune response and antibiotic therapy.
Homoplasies, indicating sites of conver-
gent evolution, are a dependable signal of
selective pressure. Eighteen homoplasic
SNPs were identified within the Beijing
lineage (Table 1). SNPs identified in rpoB,
katG, pncA promoter, embB or its pro-
moter, rpsL, rrs, and gyrA are all common
drug resistance mutations. Three homo-
plasic sites were clustered within the eis
promoter, lending substantial support
to the reported involvement of this re-
gion in conferring kanamycin resistance
(Zaunbrecher et al. 2009). The final
homoplasic SNPwas locatedwithin rpoC, which encodes the RNA
polymerase (RNAP) b9 subunit. It was found only in isolates that
carried the rifampicin-resistance–conferring mutation S450L in
rpoB, the RNAP b subunit (Table 2).
Drug resistance phenotypes and genotypes
Only three of the 33 East European Beijing isolates sequenced
exhibited a pan-susceptible phenotype to the nine antibiotics tested
(Table 3). Twenty-six were MDR, and 13 of these were classified as
XDR. All isolates that were phenotypically resistant to isoniazid, ri-
fampicin, streptomycin, and ethambutol carried mutations known
to confer resistance (Zhang et al. 1992; Finken et al. 1993; Telenti
et al. 1993, 1997; Banerjee et al. 1994).
The majority of pyrazinamide-resistant isolates harbored
nonsynonymous (ns) SNPs within pncA, which is required for
activation of the prodrug (Scorpio and Zhang 1996); however, not
all pncA mutations were associated with resistance. Notably, the
only pncA nsSNP that was not unique in the collection (I6L) did
not confer resistance. Two isolates exhibited pyrazinamide re-
sistance that could not be explained by mutation within pncA or
its promoter.
Figure 2. Maximum likelihood phylogenetic tree based on 11,854 polymorphic loci. Clades are
colored by lineage based on spoligotype analysis. The EuroAmerican lineage comprises T, Haarlem, and
LAM spoligotype families.
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For five isolates, resistance to either or both of the ribosome-
targeting antibiotics kanamycin and capreomycin could not be
attributed to rrs or eis mutations (Maus et al. 2005b; Zaunbrecher
et al. 2009). No isolates had mutations in tlyA, a gene disputably
associated with capreomycin resistance (Maus et al. 2005a;
Engstro¨m et al. 2011). To investigate possible novel drug resis-
tance mutations, we searched for commonalities in SNPs within
the terminal branches of these three strains, excluding those
associated with nonaminoglycoside drug resistance and synon-
ymous changes. The isolates did not share polymorphismswithin
any gene or promoter region, although the isolate resistant to
both antibiotics carried a SNP within Rv3728, which has simi-
larity to drug efflux proteins.
Eight of 14 isolates that were cross-resistant to the fluo-
roquinolones moxifloxacin and ofloxacin carried mutations in
gyrA, which are known to confer resistance (Takiff et al. 1994). We
investigated the co-occurrence of proximal SNPs in six isolates
with wild-type gyrA sequences that independently acquired fluo-
roquinolone resistance, but we found no commonalities that might
represent resistance mutations.
Evolution of drug resistance
Reconstruction of antibiotic-resistance genotypes and phenotypes
onto the phylogeny of the Beijing isolates, assuming parsimonious
acquisition with no reversion, enabled us to estimate the spread of
primary resistance (Fig. 4).
In this model, the pan-susceptible ancestor of clade A, be-
longing to VNTR cluster 17, acquires rifampicin, isoniazid, and
streptomycin resistance. The subsequent eis promoter and embB
mutations, conferring kanamycin and ethambutol resistance, are
coincident with a change in repeat locus 4052 to VNTR type 4 and
with further clonal expansion. In contrast, acquisition of pyr-
azinamide and fluoroquinolone resistance arises only on terminal
branches, occurring two and four times, respectively.
The expansion of clade B, from an isoniazid- and streptomycin-
resistant ancestor is associated with development of rifampicin
resistance conferring an MDR phenotype. Within this clade, both
ethambutol and kanamycin resistance are independently acquired
multiple times, including at least once by an inferred common
ancestor. Again pyrazinamide and fluoroquinolone resistance was
Figure 3. Correlation of VNTR types with SNP-derived phylogeny of the Beijing family. Branch labels show number of SNPs. VNTR loci are colored
according to the prevalence of the number of repeats at that locus. Cluster designations are given for isolates from Samara; isolates with cluster number
0 were unique in the collection.
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only sporadically acquired, on terminal branches, occurring four
and six times, respectively.
Discussion
The association of different M. tuberculosis lineages with different
geographic populations has been described (Baker et al. 2004;
Gagneux et al. 2006a). Here we show that geographical clustering
is also observed within the Beijing lineage. Within the context of
the global phylogeny of this lineage, represented by the isolates
from London, 31 of the 32 Beijing isolates from Samara clustered
together with the isolate representing the dominant clone in
Estonia (Kruuner et al. 2001). This suggests that a single ‘‘East
European’’ subtype of the Beijing lineage dominates this region.
Comparison of our polymorphisms with those defining the
Beijing K-type, dominant in Uzbekistan (Niemann et al. 2009),
indicated that K-strains belong to the East European subtype but
are not part of clades A or B.
Within the Samaran Beijing population, VNTR patterns ap-
pear relatively stable. The acquisition of drug resistance constitutes
an evolutionary bottleneck that resembles that occurring in a
transmission event. The Samaran isolates acquired resistance to up
to four different drugs without concomitant VNTR change. Thus, in
this high-incidence region, VNTR pattern identity between Beijing
strains is insufficient to corroborate an epidemiological link and
cannot be used as an indicator of recent transmission, nor can
reactivation versus exogenous reinfection be distinguished.
Although VNTR patterns of EuroAmerican strains are generally
more diverse (Brown et al. 2010), whole-genome sequencing of 36
isolates belonging to this lineage resolved an apparent outbreak from
a single 24-loci VNTR type into two separate outbreaks associated
with different clones (Gardy et al. 2011). Two further studies that
attempted to document the evolution of MDR to XDR TB by whole-
genome sequencing of isolateswith identical fingerprints found that
the isolateswerenot clonal (Ioerger et al. 2009;Niemann et al. 2009).
These data indicate that VNTR typing is of limited use as an epide-
miological tool in any region with a high-TB burden.
With one exception, the homoplasic SNPs identified were
associated with drug resistance, indicating that antibiotic therapy
exerts the primary evolutionary pressure on this M. tuberculosis
population. Accumulated evidence has
revealed that in contrast to other bacterial
pathogens, where antibiotic resistance is
frequently acquired via horizontal trans-
fer of resistance cassettes, M. tuberculosis
resistance is mediated exclusively by
chromosomal mutations affecting either
the target itself or drug modifying en-
zymes (Zhang et al. 1992; Finken et al.
1993; Telenti et al. 1993, 1997; Banerjee
et al. 1994; Takiff et al. 1994; Scorpio and
Zhang 1996; Maus et al. 2005b; Zaun-
brecher et al. 2009). This dogma is
completely supported by our data.
Rifampicin resistance is overwhelm-
ingly correlated with mutations within
a short region of the RNAP b subunit,
rpoB, which decrease drug binding af-
finity (Telenti et al. 1993). However, we
were surprised to discover a homoplasy
in the gene for the RNAP b9 subunit rpoC,
which has never been associated with
drug resistance in M. tuberculosis. Inspection of sequence data
published by Ioerger et al. (2010a) revealed that of 14 SouthAfrican
Beijing isolates sequenced, one of eight isolates carrying rpoB
S450L also carried the homoplasic rpoCmutation I491T. Again, the
rpoC mutation was not found in rifampicin-sensitive isolates or
those carrying alternate rpoB-resistance mutations.
Excluding one mutation (E1092C), which arose before the
acquisition of rifampicin resistance, all nine nsSNPs in rpoC we
identified were found exclusively in isolates carrying the rpoB
S450Lmutation, raising the possibility that they are compensatory
mutations (Table 2). Intriguingly, mutations within a short region
of rpoA, encoding the RNAPa subunit, correlatedwith the presence
of the rpoB S450L mutation and absence of rpoC mutations, sug-
gesting it could function as an alternative compensatory mecha-
nism. In competitive growth assays, Gagneux et al. (2006b) found
that the rpoB S450L mutation was associated with the lowest fit-
ness cost in laboratory mutants and no fitness cost in four out of
five clinical strains. It is possible that compensatory mutations in
rpoC or rpoA are responsible for ameliorating the fitness defect in
the clinical rpoB mutants.
Zaunbrecher et al. (2009) identified amutation in the eis gene
promoter as the source of spontaneously acquired kanamycin re-
sistance in a laboratory M. tuberculosis strain. Sequencing the eis
promoter region of clinical M. tuberculosis isolates has revealed
a strong association with kanamycin resistance that is further
supported by this study (Campbell et al. 2011; Huang et al. 2011).
The promoter mutations result in increased expression of Eis,
an aminoglycoside acetyl transferase that efficiently acetylates
and inactivates kanamycin (Zaunbrecher et al. 2009; Chen et al.
2011). Wu et al. (2009) have shown that up-regulation of eis, in
a recombinant Beijing strain, was associated with more rapid
growth in humanmonocytes. Other studies have reported that Eis
modulates secretion of pro-inflammatory cytokines, effectively
suppressing a protective immune response and suggesting a critical
role in infection outcome (Lella and Sharma 2007; Samuel et al.
2007; Shin et al. 2010). These effects of Eis expression raise the
troubling possibility that kanamycin therapy may select for mu-
tants with increased virulence, repudiating the general principle
that drug resistance leads to decreased fitness. Mutations in the eis
promoter may partly account for preservation of bacterial fitness
Table 1. Homoplasies among Samaran Beijing isolates
Gene Position SNP Substitutiona Associated resistance Reference
gyrA 7,582 A>C D94A Fluoroquinolones Takiff et al. (1994)
7,582 A>G D94G
rpoB 761,100 T>C L430P Rifampicin Telenti et al. (1993)
761,160 C>T S450L
rpoC 764,846 T>C I491T — —
rpsL 781,692 A>G K43R Streptomycin Finken et al. (1993)
781,827 A>G K88R
rrs 1,473,254 A>G 1401 Kanamycin/capreomycin Maus et al. (2005b)
katG 2,155,176 C>G S315T Isoniazid Zhang et al. (1992)
pncA 2,289,261 T>C 11 Pyrazinamide Scorpio and Zhang (1996)
eis 2,715,350 C>T 10 Kanamycin Zaunbrecher et al. (2009)
2,715,352 G>A 12
2,715,377 C>A 37
embA 4,243,224 C>T 16 Ethambutol Telenti et al. (1997)
4,243,228 C>T 12
embB 4,247,436 A>G M306V Ethambutol Telenti et al. (1997)
4,247,438 G>A M306I
4,248,010 A>G Q497R
aAmino acid substitutions are given for coding genes and nucleotide positions relative to gene start for
noncoding genes and promoter regions.
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and the extensive transmission of drug-resistant TB strains in
Samara.
By mapping drug resistance genotypes and phenotypes
onto the SNP-derived phylogenetic tree, we deduced that the
prevalence of primary and acquired resistance varied widely be-
tween antibiotics. Cases of primary MDR TB were extremely
common in the sequenced population. Expansion of clones with
mutations in ethambutol-, streptomycin-, and kanamycin-re-
sistance loci was also observed. In contrast, mutations in pncA,
conferring resistance to the commonly used first-line drug pyr-
azinamide, were only found on terminal branches, suggesting ac-
quired resistance. These data suggest that functional PncA is required
to establish a new infection. Similarly, the appearance of fluo-
roquinolone resistance, typically conferring anXDR phenotype, was
frequent but also sporadic, with no evidence of primary resistance.
Although this may partly be explained by the more recent in-
troduction of fluoroquinolone therapy, it is possible that the XDR
mutants have impaired fitness for transmission.
Most studies that purport to describe transmission of XDR
TB rely on molecular fingerprint data to infer clonality (for re-
view, see Borrell and Gagneux 2009). However, XDR strains are
typically found in regions of high-TB
prevalence where, we have shown,
clonality can only be reliably determined
through whole-genome sequencing.
Two studies have described sequence-
based investigations of XDR strains cir-
culating in South Africa. Comparison of
shared and unique polymorphisms in
the genomes of 14 Beijing isolates sug-
gested that although MDR strains were
clonally transmitted, XDR was adap-
tively acquired (Ioerger et al. 2010a). Al-
though the relatively small sample size of
this study precluded wider generaliza-
tion, the findings support our conclu-
sions. In contrast, homogeneity between
the genome sequences of eight XDR iso-
lates belonging to the EuroAmerican
KZN-type suggested clonal expansion of
this strain (Ioerger et al. 2009). The iso-
lates shared a gyrA mutation, indicating
transmission of fluoroquinolone resis-
tance; however, there was no evidence of
primary pyrazinamide resistance. Further
studies are required to determinewhether
there are genuine lineage-specific differ-
ences in the ability of drug-resistant strains
to spread.
This study provides evidence that
MDR clones have disseminated across
Samara, supporting improved infection
control as part of the wider strategy to
address drug-resistant TB. Further large-
scale sequencing projects will be neces-
sary to track the emergence and spread of
XDR TB to determine whether these
strains begin to dominate the population
or are too unfit for successful trans-
mission. Understanding the variable fit-
ness of different drug-resistant mutants
will enable treatment regimens to be tai-
lored both to meet the patients’ needs and to achieve the greatest
public health benefit.
Methods
MTBC isolates and preparation of genomic DNA
Isolates from the archives of the National Mycobacterium Reference
Laboratory, London, United Kingdom, and the Samara TB Service,
Samara Oblast, Russian Federation, were cultured on Lowenstein-
Jensen slants for 4–6 wk at 37°C. Genomic DNA was isolated using
a modification of the method described by Santos et al. (1992) and
purified using a DNeasy Blood and Tissue kit (Qiagen).
Genomic library preparation and next-generation sequencing
Genomic libraries with 200-bp inserts were prepared for se-
quencing using standard protocols according to the method de-
scribed by Harris et al. (2010). Libraries for multiplex sequencing,
of 12 isolates per lane, included indexing tags. Singleplex or
pooled indexed libraries were sequenced on an Illumina Genome
Analyzer GAII at the Wellcome Trust Sanger Institute according
Figure 4. Model of acquisition of drug resistance in Beijing isolates. SNPs conferring drug resistance
were mapped onto a cladogram of the Beijing family assuming parsimonious acquisition with no re-
version (circles); SNPs are included if the majority of isolates carrying the mutation were phenotypically
resistant (Table 3). Applying the same principle, resistance phenotypes with unknown genetic cause were
added to the tree (squares; PZA indicates pyrazinamide; KAN, kanamycin; CAP, capreomycin; and FLQ,
fluoroquinolones). Genotypes putatively acquired by an inferred common ancestor are boxed in blue.
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to the manufacturer’s protocols for generating paired-end 54-bp
reads.
Preparation of reference sequence
M. tuberculosis H37Rv was used as the reference sequence for map-
ping sequencing reads. We obtained the H37Rv strain that was
originally sequenced from the Pasteur Institute (Cole et al. 1998),
and resequenced the genome in this study.
By using iCORN (Iterative Correction of Reference Nucleo-
tides) (Otto et al. 2010), we identified 56 SNPs and seventeen 1- or
2-bp indels relative to the published H37Rv sequence (AL123456
version 4). Sixty of these polymorphisms were detected in one or
more previous H37Rv resequencing efforts (Zheng et al. 2008;
Niemann et al. 2009; Ioerger et al. 2010b). The polymorphisms
uncovered in these studies likely represent a combination of errors
in the original reference sequence and genuine differences between
H37Rv strains held in various laboratories. We used our corrected
H37Rv sequence, which has a total length of 4,411,538 bp, as the
reference genome in this study.
Annotation was downloaded from TubercuList (release R21;
http://tuberculist.epfl.ch/) and transferred onto the corrected ref-
erence sequence. Locations of repeat regions were transferred from
the EMBL sequence. The corrected annotated reference sequence is
available online (Supplemental data 2).
Identification of SNPs
Illumina sequence reads for each isolate were mapped onto the
H37Rv reference genome as paired-end reads with an insert size of
50–400 bp using SSAHA2with defaultmapping parameters, except
the minimum mapping score was increased to 30 (Ning et al.
2001). The mean mapping depth for seven M. tuberculosis isolates
with singleplex data ranged from 337- to 582-fold (mean, 479),
with 97.3%–98.8% (mean 97.8%) of the reference genome covered
by reads. Data from multiplexed isolates, or combined data from
twomultiplex runs, were excluded from further analysis if themean
mapping depth was less than 15-fold. For 51 isolates withmultiplex
data fromone or two runs,meanmapping depth ranged from 17- to
146-fold (mean, 56) and coverage of the reference genome from
93.8%–97.9% (mean, 96.3%).
Candidate SNPs were identified using ssaha_pileup (Ning
et al. 2001). SNPs that were present in <75% of reads or with
a quality score below 30 were filtered out. These parameters ef-
fectively eliminate false positives at the expense of false negatives
(Harris et al. 2010). SNPs located in annotated repeat regions or
within genes belonging to the Tuberculist categories ‘‘PE/PPE’’ or
‘‘insertion sequences and phages,’’ which are notoriously difficult
to map and/or sequence using current methodologies, were also
excluded from further analysis. A total of 408,062 bp of the ge-
nome (9.25%), including 315 CDSs, was thus excluded.
A maximum likelihood phylogeny was reconstructed using
a GTRmodel plus a gamma parameter with four categories tomodel
for among site rate variation (Stamatakis et al. 2005). Calculation of
100 bootstrap replicates provided support for nodes on the tree.
SNPs occurring on each branch of the tree were reconstructed using
DELTRAN parsimony.
Identification of LSPs
Sites of large deletions (>500 bp) were conservatively inferred by
comparison of mapping coverage plots. Where regions had zero
coverage in all strains, this was attributed to sequencing or map-
ping artifacts; regions where no reads mapped in only a subset of
strains were considered to represent genuine deletions. For East
EuropeanBeijing isolates, unmapped readswere assembleddenovo
usingVelvet (Zerbino andBirney 2008). Contigs longer than 500 bp
were mapped against completed M. tuberculosis genome sequences
(NCBI genomic BLAST; http://www.ncbi.nlm.nih.gov/sutils/genom_
table.cgi).
Molecular fingerprinting
Isolates were characterized by spoligotyping according to standard
methods (Kamerbeek et al. 1997). VNTR typing was conducted
using a panel of 15 loci (Kwara et al. 2003) or, for isolates with
a Beijing spoligotype, with a panel of eight MIRU-VNTR loci
(MIRU10, 23, 26, 31, 40; VNTR 3232, 1982, 4052) (Nikolayevskyy
et al. 2006). VNTR typing was performed in Samara by monoplex
PCR and agarose gel electrophoresis and in London using a high-
throughput method based on multiplex PCR with fluorescent-la-
beled primers followed by fragment separation on a CEQ8000
Genome Instrument (Beckman Coulter) (Brown et al. 2009).
Drug susceptibility testing
Drug susceptibility to the first-line drugs rifampicin, isoniazid,
streptomycin, and ethambutol was performed using the auto-
mated Mycobacterial Growth Indicator Tube (MGIT) 960 system
(Becton Dickinson) (Kruuner et al. 2006). For MDR isolates, suscep-
tibility to the second-line drugs kanamycin, capreomycin oflox-
acin, and moxifloxacin was also determined (Kruuner et al. 2006).
Pyrazinamide susceptibility was determined in theMGITsystem in
Samara or in semisolid media in London (Collins et al. 1997).
Data access
Raw sequence data have been submitted to the European Nucleotide
Archive (http://www.ebi.ac.uk/ena/) under accessionno. ERP000192.
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